MTIP
SUPN icon

Magee Thomson Investment Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Magee Thomson Investment Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$1K Sell
33
-26
-44% -$697 ﹤0.01% 63
2016
Q4 		$1K Buy
59
+10
+20% +$223 ﹤0.01% 64
2016
Q3 		$1K Sell
49
-20
-29% -$453 ﹤0.01% 65
2016
Q2 		$1K Sell
69
-314
-82% -$5.57K ﹤0.01% 61
2016
Q1 		$5K Buy
383
+64
+20% +$835 ﹤0.01% 42
2015
Q4 		$4K Buy
+319
New +$4.93K ﹤0.01% 84

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Magee Thomson Investment Partners's SUPN Position: Q1 2017 in Review

Magee Thomson Investment Partners reduced its Supernus Pharmaceuticals (SUPN) stake by 44% in Q1 2017, selling an estimated $697 and leaving 33 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #63.

Magee Thomson Investment Partners first reported a position in SUPN in Q4 2015 and has held it in 6 quarters since. The position peaked at $5K in Q1 2016. 246 funds tracked by Wall St. Rank hold SUPN as of Q1 2017.

  • Magee Thomson Investment Partners held 33 shares of Supernus Pharmaceuticals worth $1K as of Q1 2017.
  • Magee Thomson Investment Partners sold 26 Supernus Pharmaceuticals shares in Q1 2017, an estimated $697.
  • Supernus Pharmaceuticals made up ﹤0.01% of Magee Thomson Investment Partners's portfolio in Q1 2017, its #63 holding.
  • Magee Thomson Investment Partners first reported a position in Supernus Pharmaceuticals in Q4 2015 and has held it in 6 quarters since.
  • Magee Thomson Investment Partners's Supernus Pharmaceuticals position peaked at $5K in Q1 2016.
  • 246 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2017.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2017, filed 21 Apr 2017.